An advisory committee to the powerful US Food and Drug Administration (FDA) has voted nine to one in favour of a Mesoblast drug to treat transplant rejections in children.
The verdict was delivered by the Oncologic Drugs Advisory Committee (ODAC) about 7am AEST on Friday.
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
